{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:43:49Z","timestamp":1793396629708,"version":"4.5.0"},"reference-count":136,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG24449"],"award-info":[{"award-number":["IG24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PRIN PNRR","award":["P2022THN5N"],"award-info":[{"award-number":["P2022THN5N"]}]},{"name":"PRIN PNRR","award":["F53D23012310001"],"award-info":[{"award-number":["F53D23012310001"]}]},{"name":"Sviluppo di terapia genica e farmaci con tecnologia a RNA","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Mitochondria are multifunctional organelles that play a central role in maintaining cellular homeostasis by regulating energy metabolism, reactive oxygen species (ROS) generation, ion homeostasis, and apoptotic signaling. Dynamic processes such as mitochondrial fission, fusion, and intracellular trafficking enable cells to adapt to metabolic and environmental stress. Growing evidence indicates that dysregulation of these processes is a hallmark of cancer, contributing to metabolic reprogramming, redox imbalance, evasion of apoptosis, and disease progression. This narrative review aims to discuss the role of mitochondrial alterations in the pathophysiology of chronic myeloid leukemia (CML) and their potential therapeutic implications. Methods: Original research articles published between 2010 and 2025 were considered in this narrative review. The selected studies were critically discussed and categorized into three principal thematic domains: mitochondrial regulation of redox homeostasis, metabolic rewiring, and control of cell death pathways. Evidence was synthesized to elucidate the contribution of mitochondrial dysfunction to CML initiation, progression, and therapeutic resistance. Results: The reviewed studies highlight how mitochondrial abnormalities play a pivotal role in BCR-ABL1-driven leukemogenesis. Alterations in mitochondrial metabolism and ROS signaling support sustained proliferative signaling, promote genomic instability, and facilitate resistance to apoptosis. In addition, mitochondrial adaptations contribute to resistance to tyrosine kinase inhibitors (TKIs) and are essential for the persistence and survival of leukemic stem cells. Conclusions: Mitochondria emerge as central regulators of CML pathobiology. Therapeutic strategies targeting mitochondrial metabolism, redox homeostasis, and apoptotic signaling pathways represent promising approaches to overcoming TKI resistance and may improve clinical outcomes for patients with CML.<\/jats:p>","DOI":"10.3390\/cancers18060982","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:14:05Z","timestamp":1773843245000},"page":"982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-8279","authenticated-orcid":false,"given":"Francesco","family":"Caprino","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Valentino","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera Annunziata, 87100 Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ganino","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-168X","authenticated-orcid":false,"given":"Maria","family":"Mesuraca","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-6751","authenticated-orcid":false,"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[{"name":"Department of Science of Health, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera Annunziata, 87100 Cosenza, Italy"},{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Gallo Cantafio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic Myeloid Leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic Myeloid Leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","article-title":"BCR\/ABL P210 and P190 Cause Distinct Leukemia in Transgenic Mice","volume":"86","author":"Voncken","year":"1995","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"V The Molecular Biology of Chronic Myeloid Leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/j.1460-2075.1993.tb05797.x","article-title":"An Actin-Binding Function Contributes to Transformation by the Bcr-Abl Oncoprotein of Philadelphia Chromosome-Positive Human Leukemias","volume":"12","author":"McWhirter","year":"1993","journal-title":"EMBO J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1172\/JCI115985","article-title":"Mechanisms Underlying Abnormal Trafficking of Malignant Progenitors in Chronic Myelogenous Leukemia. Decreased Adhesion to Stroma and Fibronectin but Increased Adhesion to the Basement Membrane Components Laminin and Collagen Type IV","volume":"90","author":"Verfaillie","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1038\/sj.onc.1203940","article-title":"Bcr-Abl Protein Tyrosine Kinase Activity Induces a Loss of P53 Protein That Mediates a Delay in Myeloid Differentiation","volume":"19","author":"Pierce","year":"2000","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic Myelogenous Leukemia: Mechanisms Underlying Disease Progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1634\/theoncologist.5-5-405","article-title":"Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis","volume":"5","author":"Keeshan","year":"2000","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR\/ABL+ Leukemic Cells and Induces Apoptosis","volume":"23","author":"Mologni","year":"1997","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr\/abl Gene of the Philadelphia Chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"ref_13","first-page":"628","article-title":"The Relationship between Secondary Chromosomal Abnormalities and Blast Transformation in Chronic Myelogenous Leukemia","volume":"9","author":"Anastasi","year":"1995","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1988.6.1.180","article-title":"Definition of the Accelerated Phase of Chronic Myelogenous Leukemia","volume":"6","author":"Kantarjian","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random Karyotypic Evolution in Chronic Myeloid Leukemia","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML: Long-Term Observation of 1151 Patients from the Randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk Stratification of Chromosomal Abnormalities in Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and Prognostic Significance of 3q26.2 and Other Chromosome 3 Abnormalities in CML in the Era of Tyrosine Kinase Inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal Rearrangement Involving 11q23 Locus in Chronic Myelogenous Leukemia: A Rare Phenomenon Frequently Associated with Disease Progression and Poor Prognosis","volume":"8","author":"Wang","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-Risk Additional Chromosomal Abnormalities at Low Blast Counts Herald Death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.2022018196","article-title":"Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells","volume":"142","author":"Qiu","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41467-023-40222-z","article-title":"Pyruvate Anaplerosis Is a Targetable Vulnerability in Persistent Leukaemic Stem Cells","volume":"14","author":"Rattigan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41467-023-41167-z","article-title":"Acquired MiR-142 Deficit in Leukemic Stem Cells Suffices to Drive Chronic Myeloid Leukemia into Blast Crisis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1172\/JCI127080","article-title":"SIRT1 Regulates Metabolism and Leukemogenic Potential in CML Stem Cells","volume":"129","author":"Abraham","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2023.02.005","article-title":"NOX2 and NOX4 Control Mitochondrial Function in Chronic Myeloid Leukaemia","volume":"198","author":"Ijurko","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.12695","article-title":"Chronic Myeloid Leukemia in the Netherlands: A Population-based Study on Incidence, Treatment, and Survival in 3585 Patients from 1989 to 2012","volume":"97","author":"Thielen","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia in the Tyrosine-Kinase Inhibitor Era: Analysis of Patient Data from Six Prospective Clinical Trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of Imatinib as First-Line Treatment of Chronic Myeloid Leukemia: 10-Year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic Signatures in Cancer","volume":"381","author":"Welch","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: 2-Year Follow-up from a Randomized Phase 3 Trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: Results from the European ENEST1st Study","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2478344","DOI":"10.1080\/16078454.2025.2478344","article-title":"Second-Line Use of Dasatinib and Nilotinib in a Real-World Patient Population with Chronic Phase Chronic Myeloid Leukemia","volume":"30","author":"Toptas","year":"2025","journal-title":"Hematology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1185\/03007995.2013.789012","article-title":"Comparing Nilotinib with Dasatinib as Second-Line Therapies in Patients with Chronic Myelogenous Leukemia Resistant or Intolerant to Imatinib\u2014A Retrospective Chart Review Analysis","volume":"29","author":"Griffin","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3324\/haematol.2012.064337","article-title":"Outcome of 82 Chronic Myeloid Leukemia Patients Treated with Nilotinib or Dasatinib after Failure of Two Prior Tyrosine Kinase Inhibitors","volume":"98","author":"Rossi","year":"2013","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00277-021-04477-0","article-title":"Real-Life Comparison of Nilotinib versus Dasatinib as Second-Line Therapy in Chronic Phase Chronic Myeloid Leukemia Patients","volume":"100","author":"Scalzulli","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and Efficacy of Second-Line Bosutinib for Chronic Phase Chronic Myeloid Leukemia over a Five-Year Period: Final Results of a Phase I\/II Study","volume":"103","author":"Cortes","year":"2018","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2024-200145","article-title":"Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study","volume":"144","author":"Rousselot","year":"2024","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2024-200389","article-title":"Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)","volume":"144","author":"Breccia","year":"2024","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia after Sequential Treatment with Multiple Tyrosine Kinase Inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective Assessment of NGS-Detectable Mutations in CML Patients with Nonoptimal Response: The NEXT-in-CML Study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome\u2013Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML after 2 or More Prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-139677","article-title":"Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (Pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41556-018-0124-1","article-title":"The Multifaceted Contributions of Mitochondria to Cellular Metabolism","volume":"20","author":"Spinelli","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"189510","DOI":"10.1016\/j.bbcan.2025.189510","article-title":"Dysregulated Mitochondrial Dynamics in Cancer: Unlocking New Strategies to Combat Drug Resistance","volume":"1881","author":"Rossi","year":"2026","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12967-023-04498-5","article-title":"Mitochondrial Dysfunction at the Crossroad of Cardiovascular Diseases and Cancer","volume":"21","author":"Rocca","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gallo Cantafio, M.E., Torcasio, R., Viglietto, G., and Amodio, N. (2023). Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology. Noncoding RNA, 9.","DOI":"10.3390\/ncrna9010016"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13730","DOI":"10.1111\/cpr.13730","article-title":"bet Inhibitors (beti) Influence Oxidative Phosphorylation Metabolism by Affecting Mitochondrial Dynamics Leading to Alterations in Apoptotic Pathways in Triple-negative Breast Cancer (tnbc) Cells","volume":"57","author":"Rossi","year":"2024","journal-title":"Cell Prolif."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12967-024-05013-0","article-title":"Targeting of Mitochondrial Fission through Natural Flavanones Elicits Anti-Myeloma Activity","volume":"22","author":"Torcasio","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Becherini, P., Soncini, D., Ravera, S., Gelli, E., Martinuzzi, C., Giorgetti, G., Cagnetta, A., Guolo, F., Ivaldi, F., and Miglino, M. (2023). CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents. Antioxidants, 12.","DOI":"10.3390\/antiox12020494"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cantafio, M.E.G., Valentino, I., Torcasio, R., Ganino, L., Veneziano, C., Murfone, P., Mesuraca, M., Perrotta, I., Tallarigo, F., and Agosti, V. (2025). Mitochondrial Fission Factor Drives an Actionable Metabolic Vulnerability in Multiple Myeloma. Haematologica.","DOI":"10.3324\/haematol.2025.287526"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc3803","article-title":"Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles\u2019 Heel?","volume":"14","author":"Sabharwal","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting Cancer Cells by ROS-Mediated Mechanisms: A Radical Therapeutic Approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-023-05811-2","article-title":"BCR-ABL Triggers a Glucose-Dependent Survival Program during Leukemogenesis through the Suppression of TXNIP","volume":"14","author":"Feng","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"G\u0142owacki, S., Synowiec, E., Szwed, M., Toma, M., Skorski, T., and \u015aliwi\u0144ski, T. (2021). Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells. Biomolecules, 11.","DOI":"10.3390\/biom11040610"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101410","DOI":"10.1016\/j.molmet.2021.101410","article-title":"Antimetabolic Cooperativity with the Clinically Approved L-Asparaginase and Tyrosine Kinase Inhibitors to Eradicate CML Stem Cells","volume":"55","author":"Trinh","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","article-title":"Metabolic Alterations Mediated by STAT3 Promotes Drug Persistence in CML","volume":"35","author":"Patel","year":"2021","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 Regulates Energy Metabolism, Differentiation and Survival of Philadelphia-Chromosome-Positive Cells","volume":"12","author":"Karvela","year":"2016","journal-title":"Autophagy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41419-022-05028-9","article-title":"Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia","volume":"13","author":"Houshmand","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive Oxygen Species in Cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bcp.2018.05.018","article-title":"Taxodione Induces Apoptosis in BCR-ABL-Positive Cells through ROS Generation","volume":"154","author":"Uchihara","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"116625","DOI":"10.1016\/j.taap.2023.116625","article-title":"Amsacrine Downregulates BCL2L1 Expression and Triggers Apoptosis in Human Chronic Myeloid Leukemia Cells through the SIDT2\/NOX4\/ERK\/HuR Pathway","volume":"474","author":"Lee","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3892\/mmr.2014.2381","article-title":"Low-Dose Radiation-Induced Apoptosis in Human Leukemia K562 Cells through Mitochondrial Pathways","volume":"10","author":"Xin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18111","DOI":"10.3390\/ijms160818111","article-title":"UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib","volume":"16","author":"Synowiec","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1002\/ctm2.317","article-title":"A Folate Receptor 3 SNP Promotes Mitochondria-induced Clonogenicity of CML Leukemia Cells: Implications for Treatment Free Remission","volume":"11","author":"Shen","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41388-020-01547-x","article-title":"AMD1 Is Required for the Maintenance of Leukemic Stem Cells and Promotes Chronic Myeloid Leukemic Growth","volume":"40","author":"Sari","year":"2021","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.niox.2016.06.002","article-title":"High Oxidative Stress Adversely Affects NF\u03baB Mediated Induction of Inducible Nitric Oxide Synthase in Human Neutrophils: Implications in Chronic Myeloid Leukemia","volume":"58","author":"Singh","year":"2016","journal-title":"Nitric Oxide"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16348","DOI":"10.3390\/ijms140816348","article-title":"The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR\/ABL-Expressing Cells to Tyrosine Kinase Inhibitors","volume":"14","author":"Glowacki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10495-012-0739-9","article-title":"Increased Acetylation of Lysine 317\/320 of P53 Caused by BCR-ABL Protects from Cytoplasmic Translocation of P53 and Mitochondria-Dependent Apoptosis in Response to DNA Damage","volume":"17","author":"Wolanin","year":"2012","journal-title":"Apoptosis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/jpet.110.172536","article-title":"A New Nonpeptidic Inhibitor of 14-3-3 Induces Apoptotic Cell Death in Chronic Myeloid Leukemia Sensitive or Resistant to Imatinib","volume":"336","author":"Mancini","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo","volume":"13","author":"Beider","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib Induces Lung Vascular Toxicity and Predisposes to Pulmonary Hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"eabd5016","DOI":"10.1126\/scitranslmed.abd5016","article-title":"ULK1 Inhibition Promotes Oxidative Stress\u2013Induced Differentiation and Sensitizes Leukemic Stem Cells to Targeted Therapy","volume":"13","author":"Ianniciello","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Kluza, J., Jendoubi, M., Ballot, C., Dammak, A., Jonneaux, A., Idziorek, T., Joha, S., Dauphin, V., Malet-Martino, M., and Balayssac, S. (2011). Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021924"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Curcio, A., Rocca, R., Chiera, F., Gallo Cantafio, M.E., Valentino, I., Ganino, L., Murfone, P., De Simone, A., Di Napoli, G., and Alcaro, S. (2024). Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations. Antioxidants, 13.","DOI":"10.3390\/antiox13111427"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"117552","DOI":"10.1016\/j.ejmech.2025.117552","article-title":"O-Derivatization of Natural Tropolone and \u03b2-Thujaplicin Leading to Effective Inhibitors of Human Carbonic Anhydrases IX and XII","volume":"290","author":"Melfi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Marchese, E., Gallo Cantafio, M.E., Ambrosio, F.A., Torcasio, R., Valentino, I., Trapasso, F., Viglietto, G., Alcaro, S., Costa, G., and Amodio, N. (2023). New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome Inhibitors. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121712"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Todoerti, K., Gallo Cantafio, M.E., Oliverio, M., Juli, G., Rocca, C., Citraro, R., Tassone, P., Procopio, A., De Sarro, G., and Neri, A. (2021). Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111639"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Juli, G., Oliverio, M., Bellizzi, D., Gallo Cantafio, M.E., Grillone, K., Passarino, G., Colica, C., Nardi, M., Rossi, M., and Procopio, A. (2019). Anti-Tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. Cancers, 11.","DOI":"10.3390\/cancers11070990"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2300538","DOI":"10.1002\/adbi.202300538","article-title":"Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria-Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1","volume":"8","author":"An","year":"2024","journal-title":"Adv. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41419-022-04842-5","article-title":"Mitochondrial Oxidative Phosphorylation Is Dispensable for Survival of CD34+ Chronic Myeloid Leukemia Stem and Progenitor Cells","volume":"13","author":"Yan","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"115875","DOI":"10.1016\/j.bcp.2023.115875","article-title":"Mitochondrial Complex I Inhibition by Homoharringtonine: A Novel Strategy for Suppression of Chronic Myeloid Leukemia","volume":"218","author":"Han","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijbiomac.2016.01.069","article-title":"CR-LAAO Antileukemic Effect against Bcr-Abl+ Cells Is Mediated by Apoptosis and Hydrogen Peroxide","volume":"86","author":"Burin","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41419-020-2304-8","article-title":"Tetrahydrobenzimidazole TMQ0153 Triggers Apoptosis, Autophagy and Necroptosis Crosstalk in Chronic Myeloid Leukemia","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2018.02.063","article-title":"Antibiotic Ivermectin Selectively Induces Apoptosis in Chronic Myeloid Leukemia through Inducing Mitochondrial Dysfunction and Oxidative Stress","volume":"497","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.bcp.2010.08.013","article-title":"Involvement of ROS in Chlorogenic Acid-Induced Apoptosis of Bcr-Abl+ CML Cells","volume":"80","author":"Rakshit","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tiv.2011.12.018","article-title":"Anti-Leukemic Effects of Gallic Acid on Human Leukemia K562 Cells: Downregulation of COX-2, Inhibition of BCR\/ABL Kinase and NF-\u039aB Inactivation","volume":"26","author":"Aparna","year":"2012","journal-title":"Toxicol. In Vitro"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"115934","DOI":"10.1016\/j.bcp.2023.115934","article-title":"Hydroquinone-Selected Chronic Myelogenous Leukemia Cells Are Sensitive to Chloroquine-Induced Cytotoxicity via MCL1 Suppression and Glycolysis Inhibition","volume":"218","author":"Chiou","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations","volume":"21","author":"Gregory","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1038\/cddis.2013.190","article-title":"Organopalladium Compound 7b Targets Mitochondrial Thiols and Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells","volume":"4","author":"Moraes","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 Induces Apoptosis of Imatinib-Resistant Chronic Myelogenous Leukemia with T315I Mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ijc.29407","article-title":"ST1926, an Orally Active Synthetic Retinoid, Induces Apoptosis in Chronic Myeloid Leukemia Cells and Prolongs Survival in a Murine Model","volume":"137","author":"Nasr","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2014.03.012","article-title":"HS-438, a New Inhibitor of Imatinib-Resistant BCR-ABL T315I Mutation in Chronic Myeloid Leukemia","volume":"348","author":"Yun","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"115852","DOI":"10.1016\/j.taap.2021.115852","article-title":"Role of Ferroptosis in Promoting Cardiotoxicity Induced by Imatinib Mesylate via Down-Regulating Nrf2 Pathways in Vitro and in Vivo","volume":"435","author":"Song","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Wong, S.-M., Liu, F.-H., Lee, Y.-L., and Huang, H.-M. (2016). MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148093"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2013.06.007","article-title":"The Hsp90 Inhibitor SNX-2112, Induces Apoptosis in Multidrug Resistant K562\/ADR Cells through Suppression of Akt\/NF-\u039aB and Disruption of Mitochondria-Dependent Pathways","volume":"205","author":"Wang","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/pmic.201000720","article-title":"2-D Gel Electrophoresis-based Proteomic Analysis Reveals That Ormeloxifen Induces G0\u2013G1 Growth Arrest and ERK-mediated Apoptosis in Chronic Myeloid Leukemia Cells K562","volume":"11","author":"Pal","year":"2011","journal-title":"Proteomics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1248\/bpb.b12-00537","article-title":"Activation of C-Jun N-Terminal Kinase Mediates Tanshinone IIA-Induced Apoptosis in KBM-5 Chronic Myeloid Leukemia Cells","volume":"36","author":"Yun","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"114857","DOI":"10.1016\/j.taap.2019.114857","article-title":"Autophagic HuR MRNA Degradation Induces Survivin and MCL1 Downregulation in YM155-Treated Human Leukemia Cells","volume":"387","author":"Chiou","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Bonifacio, M., Rigo, A., Guardalben, E., Bergamini, C., Cavalieri, E., Fato, R., Pizzolo, G., Suzuki, H., and Vinante, F. (2012). \u03b1-Bisabolol Is an Effective Proapoptotic Agent against BCR-ABL+ Cells in Synergism with Imatinib and Nilotinib. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046674"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1016\/j.biomaterials.2011.04.043","article-title":"Sustained Targeting of Bcr-Abl+ Leukemia Cells by Synergistic Action of Dual Drug Loaded Nanoparticles and Its Implication for Leukemia Therapy","volume":"32","author":"Acharya","year":"2011","journal-title":"Biomaterials"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","article-title":"Mitochondria and Cancer","volume":"166","author":"Vyas","year":"2016","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of Cancer Metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2016.67","article-title":"Development and Analysis of Patient-Derived Xenograft Mouse Models in Intravascular Large B-Cell Lymphoma","volume":"30","author":"Shimada","year":"2016","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.freeradbiomed.2016.11.035","article-title":"An MtDNA Mutation Accelerates Liver Aging by Interfering with the ROS Response and Mitochondrial Life Cycle","volume":"102","author":"Niemann","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","article-title":"Down-Regulation of Mitochondrial ATPase by Hypermethylation Mechanism in Chronic Myeloid Leukemia Is Associated with Multidrug Resistance","volume":"21","author":"Li","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/jasms.3c00103","article-title":"Analysis of the Inhibitory Effect of Hsa-MiR-145-5p and Hsa-MiR-203a-5p on Imatinib-Resistant K562 Cells by GC\/MS Metabolomics Method","volume":"34","author":"Singh","year":"2023","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"33769","DOI":"10.18632\/oncotarget.5615","article-title":"Pyrvinium Selectively Targets Blast Phase-Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eadi5336","DOI":"10.1126\/scitranslmed.adi5336","article-title":"Nutrient-Sensitizing Drug Repurposing Screen Identifies Lomerizine as a Mitochondrial Metabolism Inhibitor of Chronic Myeloid Leukemia","volume":"16","author":"Khalaf","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","article-title":"Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors","volume":"27","author":"Rothe","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/mc.22587","article-title":"Survivin Inhibitor YM155 Induces Mitochondrial Dysfunction, Autophagy, DNA Damage and Apoptosis in Bcl-xL Silenced Glioma Cell Lines","volume":"56","author":"Jane","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"105207","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a Potential Anticancer Drug Derived from an Antiparasitic Drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","article-title":"The Pathophysiology of Mitochondrial Cell Death","volume":"305","author":"Green","year":"2004","journal-title":"Science"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 Family: Regulators of the Cellular Life-or-Death Switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bcmd.2010.07.011","article-title":"BAX\/BCL-XL Gene Expression Ratio Inversely Correlates with Disease Progression in Chronic Myeloid Leukemia","volume":"45","author":"Gonzalez","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1179\/102453310X12583347009775","article-title":"Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells with Wild-Type BCR\u2013ABL, as Effectively as in Parental Sensitive Counterparts","volume":"15","author":"Ekiz","year":"2010","journal-title":"Hematology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10495-010-0457-0","article-title":"Enhancement of Imatinib-Induced Apoptosis of BCR\/ABL-Expressing Cells by Nutlin-3 through Synergistic Activation of the Mitochondrial Apoptotic Pathway","volume":"15","author":"Kurosu","year":"2010","journal-title":"Apoptosis"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopha.2012.10.017","article-title":"Dihydroartemisinin Inhibits the Bcr\/Abl Oncogene at the MRNA Level in Chronic Myeloid Leukemia Sensitive or Resistant to Imatinib","volume":"67","author":"Lee","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a Novel Tyrosine Kinase Inhibitor, Synergistically Induce Apoptosis in Imatinib-Resistant Chronic Myelogenous Leukemia Cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41419-017-0075-7","article-title":"Anthelmintic Niclosamide Suppresses Transcription of BCR-ABL Fusion Oncogene via Disabling Sp1 and Induces Apoptosis in Imatinib-Resistant CML Cells Harboring T315I Mutant","volume":"9","author":"Jin","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-11-1971","article-title":"Cyclin-Dependent Kinase 7\/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor \u03b1 and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells","volume":"18","author":"Wu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00277-011-1212-5","article-title":"A Novel Mechanism of Dasatinib-Induced Apoptosis in Chronic Myeloid Leukemia; Ceramide Synthase and Ceramide Clearance Genes","volume":"90","author":"Gencer","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 Increases Tyrosine Kinase Inhibitor\u2013Induced Apoptosis in Chronic Myeloid Leukemia Cells through XIAP Downregulation and Sensitizes CD34+ CD38\u2212 Population to Imatinib","volume":"40","author":"Airiau","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3892\/ijo.2016.3382","article-title":"Hsp90 Inhibitor, BIIB021, Induces Apoptosis and Autophagy by Regulating MTOR-Ulk1 Pathway in Imatinib-Sensitive and -Resistant Chronic Myeloid Leukemia Cells","volume":"48","author":"He","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","article-title":"Role of Mitochondria in Ferroptosis","volume":"73","author":"Gao","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy","volume":"334","author":"Chonghaile","year":"2011","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40364-024-00594-w","article-title":"Antileukemic Potential of Methylated Indolequinone MAC681 through Immunogenic Necroptosis and PARP1 Degradation","volume":"12","author":"Lorant","year":"2024","journal-title":"Biomark. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:28:21Z","timestamp":1773844101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":136,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060982"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060982","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}